The National Cancer Institute has awarded Mount Sinai researchers $3.15 million in grant funding to assess the potential of a multidisciplinary drug development platform to identify new biological targets for precision-based therapeutics for hepatocellular carcinoma.
[Mount SInai]
Sorry, but the selected Zotpress account can't be found.